Drug intelligence / Profile preview

WPC04

Development stage: Preclinical
Lead developer: Westlake Pharmaceuticals
Modality: Small Molecules

Overview

WPC04 is a small molecule therapeutic candidate currently in the drug discovery stage, developed by Westlake Pharmaceuticals (Westlake Biopharmaceutical). It is designed to target the Mitogen-Activated Protein Kinase (MAPK) signaling pathway, which is frequently dysregulated in various types of cancer, leading to uncontrolled cell proliferation and survival. As a MAPK pathway inhibitor, WPC04 is being investigated for its potential to treat solid tumors and other malignancies where this signaling cascade is aberrantly activated.

Targets

MEK

Beyond the preview

Go deeper on WPC04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WPC04.

Explore the full profile